

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: )  
)  
**Josephus H. M. LANGE et al.** )  
) **Group Art Unit: Not Yet Assigned**  
Serial No.: **Not Yet Assigned** )  
) **Examiner: Not Yet Assigned**  
Filed: **September 16, 2003** )  
)  
For: **1H-1,2,4-TRIAZOLE-3-CARBOXAMIDE** )  
**DERIVATIVES HAVING CANNABINOID-CB<sub>1</sub>** )  
**RECEPTOR AGONISTIC, PARTIAL** )  
**AGONISTIC, INVERSE AGONISTIC OR** )  
**ANTAGONISTIC ACTIVITY** )

**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450**

Sir:

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§1.56 and 1.97(b), applicants bring to the Examiner's attention the documents listed on attached Form PTO-1449. Copies of the listed documents are attached. Applicants respectfully request that the Examiner consider the documents listed on attached Form PTO-1449 and indicate that they were considered by making an appropriate notation on this form. This Information Disclosure Statement is being filed with the above-referenced application.

The following is listed on the accompanying PTO-1449 and is in a non-English language:

1. CLERIN, D. et al., "№ 42. – Hétérocyclisation des  $\alpha$ -acylaminoamides. III – Propriétés des amino-5 oxazoles", Bull. Soc. Chim. Fr., No. 1-2, Pt.2, pp. 211-217,

(1974) - The relevance of this document is discussed at page 2 of the specification of the present application.


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents. Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: September 16, 2003

By:   
Ernest F. Chapman  
Reg. No. 25,961

Enclosures  
EFC/FPD/sci

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

## INFORMATION DISCLOSURE CITATION

Atty. Docket No.	01975.0047	Serial No.	Not Yet Assigned
Applicants	Josephus H. M. LANGE et al.		
Filing Date	September 16, 2003	Group:	Not Yet Assigned

U.S. PATENT DOCUMENTS							
Examiner Initial*		Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	JAGEROVIC, N. et al., "A Novel Class of Heterocyclic Cannabinoids: Design, Preparation, In Vitro and In Vivo Studies of 1,2,4-Triazoles", Drugs Fut 2002, Vol. 27 (Suppl. A): XVII <sup>th</sup> Int. Symp. on Medical Chemistry, pp. 271, (2002).
	HARHASH, A. H. et al., "Reactions of 2-Aryl-4-aryldrazonon <sup>-Δ2</sup> -oxazonlin-5-ones with Acid Amides & Diamines", Indian Journal of Chemistry, Vol. 14B, pp. 268-272, (April 1976).
	ELNAGDI, M. H. et al., "Studies with Polyfunctionally Substituted Heteroaromatics: 2-Phenyl-4-p-Tolyldrazono-2-oxazoline-5-one as a Precursor for the Synthesis of Substituted 1,2,4-Triazoles and Pyridines", Heteroatom Chemistry, Vol. 6, No. 6, pp. 589-592, (1995).
	CLERIN, D. et al., "№ 42. – Hétérocyclisation des α-acylaminoamides. III – Propriétés des amino-5 oxazoles", Bull. Soc. Chim. Fr., No. 1-2, Pt.2, pp. 211-217, (1974).

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce